Orchestra BioMed CEO buys 10K shares at $4.79
Rhea-AI Filing Summary
Orchestra BioMed Holdings, Inc. (OBIO) reported that Chief Executive Officer and Chairperson David P. Hochman purchased 10,000 shares of common stock on September 3, 2026 in an open-market or private transaction at a weighted average price of $4.79 per share, with individual prices ranging from $4.73 to $4.79. Following this purchase, he directly holds 1,070,746 common shares, in addition to several indirect holdings through family trusts.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 10,000 shares
Net Buy
6 txns
Insider
Hochman David P
Role
See Remarks
Bought
10,000 shs ($48K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock, par value $0.0001 per share ("Common Stock") F1 | 10,000 | $4.79 | $48K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock, par value $0.0001 per share ("Common Stock") — 1,070,746 shares (Direct);
Common Stock — 436,199 shares (Indirect, By the DPH 2008 Trust);
Common Stock — 2,000 shares (Indirect, By the Solomon Ascher Hochman 2019 Trust);
Common Stock — 2,000 shares (Indirect, By the Hannah Hochman 2019 Trust);
Common Stock — 2,000 shares (Indirect, By the Judah Herman Hochman 2019 Trust);
Common Stock — 3,140 shares (Indirect, By the NSH 2008 Family Trust)
Footnotes (1)
- F1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.73 to $4.79. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Key Figures
Shares purchased: 10,000 shares
Weighted average purchase price: $4.79 per share
Purchase price range: $4.73–$4.79 per share
+4 more
7 metrics
Shares purchased
10,000 shares
Common stock bought by David P. Hochman on September 3, 2026
Weighted average purchase price
$4.79 per share
Price for the 10,000 OBIO shares purchased on September 3, 2026
Purchase price range
$4.73–$4.79 per share
Range of prices for the 10,000 OBIO shares bought on September 3, 2026
Direct holdings after transaction
1,070,746 shares
Direct common stock position of David P. Hochman after the purchase
DPH 2008 Trust holdings
436,199 shares
Indirect holdings of OBIO common stock by the DPH 2008 Trust
NSH 2008 Family Trust holdings
3,140 shares
Indirect holdings of OBIO common stock by the NSH 2008 Family Trust
Each 2019 Trust holdings
2,000 shares
Indirect OBIO common stock held by each named 2019 trust
Key Terms
weighted average price, open market or private transaction, indirect ownership, family trust
4 terms
weighted average price financial
"The price reported is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open market or private transaction financial
"Purchase in open market or private transaction"
indirect ownership financial
"By the DPH 2008 Trust"
family trust financial
"By the NSH 2008 Family Trust"
FAQ
What did OBIO’s CEO David P. Hochman report in this Form 4?
He reported purchasing 10,000 shares of Orchestra BioMed common stock on September 3, 2026 in an open-market or private transaction at a weighted average price of $4.79 per share, with trade prices between $4.73 and $4.79.
What indirect OBIO holdings does David P. Hochman report through trusts?
He reports indirect holdings of Orchestra BioMed common stock, including 436,199 shares held by the DPH 2008 Trust, 2,000 shares by each of three 2019 trusts, and 3,140 shares by the NSH 2008 Family Trust.
Does this OBIO Form 4 report any insider sales or only purchases?
This Form 4 reports only a purchase of 10,000 shares of Orchestra BioMed common stock by David P. Hochman on September 3, 2026. It does not report any sales of OBIO shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
